HOME >> BIOLOGY >> NEWS
Former White House science advisor warns that nanotechnology's potential threatened

d engineering education almost fifty years ago when Russia launched Sputnikthe worlds first artificial satellite. He stressed that Americas "children and workforce need that same level of national commitment to lead and keep them competitive in the Nano Age."

Finally, Lane called for "a deliberate effort to provide the public with balanced and easily understood information about nanotechnologys potential benefits and its possible risks and for more public engagement"led by government, industry and the science and engineering community working together.

"From the beginning, an explicit aim of the U.S. National Nanotechnology Initiative (NNI)a $6.5 billion federal investment in nanotechnology research launched in January 2000 under President Bill Clintonwas to excite young girls and boys about science, particularly the physical sciences and engineering. The intent was to reach millions of children using the wonders of nanotechnology to encourage them to study science and to equip them to compete successfully at the cutting-edge of a globalized economy." Another stated NNI goal was "to establish channels of communication, providing information to, and seeking input from, the public at large regarding the federal nanotechnology program. But so far, government-supported childrens education programs and public outreach efforts have been long on rhetoric and short on the strategy and resources necessary to achieve significant results," Lane said.

Lane is one of four co-authors of "What drives public acceptance of nanotechnology""a paper which presents the results of the first large-scale empirical study of how consumers consider risks and benefits when deciding whether to purchase or use specific nanotechnology products. The articles lead author is Steven C. Currall, University of College London and London Business School. (For information on the article, U.S. journalists should contact Jade Boyd, News & Media Relations, Rice University, by
'"/>

Contact: Julia Moore
julia.moore@wilsoncenter.org
202-691-4025
Project on Emerging Nanotechnologies
5-Dec-2006


Page: 1 2 3

Related biology news :

1. Former Interior Secretary Bruce Babbitt to speak at Yale Dam Conference
2. White blood cells are picky about sugar
3. UTSA neurobiologist awarded $225,000 from Whitehall Foundation
4. Whiteflies and plant viruses can help each other to speed up biological invasion
5. Whitefly spreads emerging plant viruses
6. White blood cells in lung produce histamine seen in allergies
7. White blood cells of cancer-resistant mice overwhelm natural defenses of cancer cells
8. White blood cells from cancer-resistant mice cure cancers in ordinary mice
9. White-coat effect is virtually eliminated using a non-drug hypertension
10. Great White shark evolution debate involves WSU Lake Campus geology professor
11. White blood cell waste disposal system plays critical regulatory role

Post Your Comments:
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: